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ABSTRACT Viral protein R (Vpr) is an HIV-1 accessory protein whose function re-
mains poorly understood. In this report, we sought to determine the requirement of
Vpr for facilitating HIV-1 infection of monocyte-derived dendritic cells (MDDCs), one
of the first cell types to encounter virus in the peripheral mucosal tissues. In this re-
port, we characterize a significant restriction of Vpr-deficient virus replication and
spread in MDDCs alone and in cell-to-cell spread in MDDC-CD4 T cell cocultures.
This restriction of HIV-1 replication in MDDCs was observed in a single round of vi-
rus replication and was rescued by the expression of Vpr in trans in the incoming vi-
rion. Interestingly, infections of MDDCs with viruses that encode Vpr mutants unable
to interact with either the DCAF1/DDB1 E3 ubiquitin ligase complex or a host factor
hypothesized to be targeted for degradation by Vpr also displayed a significant rep-
lication defect. While the extent of proviral integration in HIV-1-infected MDDCs was
unaffected by the absence of Vpr, the transcriptional activity of the viral long termi-
nal repeat (LTR) from Vpr-deficient proviruses was significantly reduced. Together,
these results characterize a novel postintegration restriction of HIV-1 replication in
MDDCs and show that the interaction of Vpr with the DCAF1/DDB1 E3 ubiquitin li-
gase complex and the yet-to-be-identified host factor might alleviate this restriction
by inducing transcription from the viral LTR. Taken together, these findings identify
a robust in vitro cell culture system that is amenable to addressing mechanisms un-
derlying Vpr-mediated enhancement of HIV-1 replication.
IMPORTANCE Despite decades of work, the function of the HIV-1 protein Vpr re-
mains poorly understood, primarily due to the lack of an in vitro cell culture system
that demonstrates a deficit in replication upon infection with viruses in the absence
of Vpr. In this report, we describe a novel cell infection system that utilizes primary
human dendritic cells, which display a robust decrease in viral replication upon in-
fection with Vpr-deficient HIV-1. We show that this replication difference occurs in a
single round of infection and is due to decreased transcriptional output from the in-
tegrated viral genome. Viral transcription could be rescued by virion-associated Vpr.
Using mutational analysis, we show that domains of Vpr involved in binding to the
DCAF1/DDB1/E3 ubiquitin ligase complex and prevention of cell cycle progression
into mitosis are required for LTR-mediated viral expression, suggesting that the evo-
lutionarily conserved G2 cell cycle arrest function of Vpr is essential for HIV-1 replica-
tion.
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Human immunodeficiency virus type 1 (HIV-1) encodes a number of proteins thatallow entry and replication in human cells. In addition to the structural or enzy-
matic proteins that have well-defined functions in the replication cycle, there are also
a number of small, accessory proteins. Accessory proteins encoded by HIV-1 are not
always necessary for replication in vitro but are absolutely essential for replication in
vivo (1). These proteins serve to counteract host restriction factors that would normally
limit HIV-1 infection (1, 2). Of the accessory proteins encoded by HIV-1, Vpr is the only
one whose function remains relatively unclear.
Vpr is a small, 96-amino-acid, 14-kDa protein that is packaged into the budding
virion through associations with the p6 region of Gag (3–10). This association allows Vpr
to be present in the cell at a relatively high quantity (200 to 300 molecules/virion)
upon initial infection (11). Previous studies have extensively characterized the outcome
of Vpr expression in various cell types. In cycling cells, Vpr expression results in G2/M
cell cycle arrest, which culminates in the induction of apoptosis (12–14). It is well
established that Vpr-mediated G2/M cell cycle arrest is mediated through its association
with the Cul4A/DCAF/DDB1 E3 (CRL4DCAF1) ubiquitin ligase complex (15–17). In addi-
tion, HIV-1 Vpr has been shown to recruit and degrade a number of DNA damage
response (DDR) proteins, including the SLX4-SLX1/MUS81-EME1 structure-specific en-
donuclease complex (SLX4com), uracil DNA glycosylase 2 (UNG2), and helicase-like
transcription factor (HLTF) (18–21), via the CRL4DCAF1 complex, resulting in G2/M cell
cycle arrest, although the role that this process plays during HIV-1 infection still remains
unclear.
Although a number of previous studies have examined the requirement of Vpr for
HIV-1 replication in various cell types, including primary CD4 T cells and monocyte-
derived macrophages (MDMs), differences in virus replication have not been consis-
tently observed (18, 20, 22–26). Vpr expression is dispensable for infection in activated
CD4 T cells in vitro (22–25, 27), presumably due to the well-characterized cytostatic
and cytopathic functions of Vpr in cycling cells (12). In contrast, recent studies with
MDMs suggest that Vpr is necessary for HIV-1 envelope (Env) expression, and the
purported consequence of infection of MDMs with Vpr-deficient viruses was reported
to be decreased viral production and reduced cell-to-cell spread to CD4 T cells (22,
28). Notably, there has been considerable heterogeneity in replication differences
between wild-type (WT) and Vpr-deficient viruses and host responses to virus infection
in MDMs, presumably due to donor and experimental variability between studies (12,
29, 30). Additionally, it has also been reported that Vpr expression in macrophages can
both inhibit and induce type I interferon (IFN) responses (18, 28, 31–34).
Dendritic cells (DCs) are sentinel cells that bridge innate and adaptive immunity (35).
They actively patrol peripheral tissues, including mucosal sites of HIV-1 transmission, in
search of foreign pathogens. Because of this, monocyte-derived DCs (MDDCs) are
among the first cells to interact with HIV-1 upon sexual transmission of the virus
(36–40). While MDDCs are less susceptible to infection than activated CD4 T cells and
macrophages, they are still able to be infected ex vivo at a low but consistent level
(41–44). In contrast to work with MDMs and CD4 T cells, there have been isolated
descriptions of the effects of Vpr on the HIV-1 replicative capacity in MDDCs (41, 44),
with no consensus on the mechanisms accounting for the Vpr-mediated enhancement
of virus replication. In this study, we use MDDCs as a model system to investigate the
role of Vpr during infection. We find a robust replication defect of Vpr-deficient HIV-1
in MDDCs, and contrary to previous studies (44), the replication defect was not due to
decreased Env expression in Vpr-deficient HIV-1-infected cells. Rather, the block of ΔVpr
virus infection was at the step of viral transcription and could be rescued by the
addition of Vpr in trans into the virion in a single-round-infection analysis. We found
that mutations Vpr-Q65R and Vpr-H71R, which ablate the association of Vpr with the
CRL4DCAF1 complex, or Vpr-R90K, which does not induce G2 cell cycle arrest (17, 45–50),
displayed similar decreases in replication and viral transcription in a single round of
infection. Together, these data show a novel postintegration block to HIV-1 replication
in MDDCs at the point of viral transcription that is alleviated by virion-associated Vpr.
Miller et al. Journal of Virology
July 2017 Volume 91 Issue 13 e00051-17 jvi.asm.org 2
RESULTS
Vpr-deficient viruses display a replication defect in DCs. HIV-1 replication in
MDDCs is restricted at the reverse transcription (RT) step by SAMHD1, which controls
the size of cytosolic deoxynucleoside triphosphate (dNTP) pools (51, 52). Despite the
presence of SAMHD1, MDDCs remain susceptible to HIV-1 infection in vitro at a low but
measurable level (44, 53–55). We infected MDDCs with the replication-competent WT
or Vpr-deficient (ΔVpr) CCR5-tropic Lai-YU2 virus and harvested cells for the determi-
nation of intracellular p24Gag expression levels by flow cytometry analysis at 3 days
postinfection. The input for these infections was normalized based on the infectious
titer of the viruses on TZM-bl cells. As expected, CD11c DC-SIGN MDDCs were
susceptible to viral infection albeit at low levels (Fig. 1A and B). Interestingly, Lai-YU2/
ΔVpr failed to establish robust infection in MDDCs (Fig. 1A and B), and there was a
reproducible 3- to 5-fold decrease in the percentage of p24Gag cells in ΔVpr virus
infections compared to WT virus infections (Fig. 1B). To determine the functional
consequences of Vpr deficiency on virus spread, DCs and phytohemagglutinin (PHA)/
interleukin-2 (IL-2)-activated CD4 T cells were infected with infectious viruses (multi-
plicity of infection [MOI] of 1), and cell-free culture supernatants were harvested every
3 days and analyzed for p24Gag content by an enzyme-linked immunosorbent assay
(ELISA). While there was some donor variability, Lai-YU2/ΔVpr infection of MDDCs
derived from 3 independent donors consistently resulted in significantly lower levels of
replication than did wild-type Lai-YU2 infection (Fig. 1C). In contrast to the substantial
attenuation of virus spread in Lai-YU2/ΔVpr-infected DCs, both viruses replicated to
similar extents in activated CD4 T cells (Fig. 1E), in agreement with data from
previously reported studies (22–25, 27). These results suggest that Vpr plays an impor-
tant role in facilitating HIV-1 infection of DCs.
Numerous studies have demonstrated robust HIV-1 replication in DC-T cell cocul-
tures at levels higher than those observed in infections of either cell type alone and is
dependent on the rapid, highly efficient transmission of DC-derived progeny virions to
CD4 T cells across infectious synapses (42, 43, 54–60). We sought to determine the
effect, if any, of Vpr deficiency on DC-mediated virus spread to CD4 T cells. MDDCs
were first infected with wild-type Lai-YU2 or Lai-YU2/ΔVpr and cultured for 2 days, prior
to the initiation of coculture with autologous activated CD4 T cells (Fig. 1D). There was
a substantial enhancement of virus replication in cocultures infected with the WT virus,
compared to ΔVpr virus infections (7-fold increase) (Fig. 1E and F). Interestingly, the
difference between WT and ΔVpr virus replication in DC-T cell cocultures was greater
than that observed in infections of MDDCs or CD4 T cells alone (Fig. 1E and F).
Together, these results suggest that the replication defect observed in MDDCs infected
with HIV-1/ΔVpr translates to CD4 T cells during cell-to-cell contact and transmission.
Defects in Vpr infection are independent of viral glycoprotein expression.
Previous studies suggested a requirement for Vpr in maintaining robust HIV-1 gp120
expression in MDMs and MDDCs by counteracting a myeloid cell-intrinsic mechanism
of Env degradation (22, 28, 44). To begin to understand the underlying mechanism
accounting for the replication defect of HIV-1/ΔVpr in DCs, we examined viral protein
expression in MDDCs infected with wild-type Lai-YU2 or Lai-YU2/ΔVpr (MOI  3).
Infected cells were lysed at 6 days postinfection for quantitative Western blot analysis.
We did not observe any steady-state differences in gp120 expression levels when
values were normalized to Gag (p55 and p24) levels in MDDCs infected with the WT or
ΔVpr virus (Fig. 2A). Quantification of immunoblots from infected MDDC lysates derived
from four independent donors showed no significant differences in gp120 expression
(Fig. 2B). We next sought to determine if Vpr deficiency might result in decreased
gp120 incorporation into virus particles derived from productively infected DCs. MDDC
culture supernatants were harvested on multiple days postinfection, and pooled su-
pernatants were concentrated over a sucrose cushion prior to Western blot analysis. We
again failed to observe any significant differences in the levels of gp120 incorporation
between virus particles derived from WT-infected MDDCs and those derived from
ΔVpr-infected MDDCs (Fig. 2C and D). The consistency of the replication defect of
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FIG 1 Infection with Vpr-deficient HIV-1 results in attenuated virus replication in MDDCs and MDDC-T cell cocultures. (A) FACS profiles of mock-infected
MDDCs or MDDCs infected with Lai-YU2 or Lai-YU2/ΔVpr (MOI  1) at day 3 postinfection. Cells were stained for CD11c, DC-SIGN, and p24Gag. From left
to right, the plots shown depict the gating strategy for the flow cytometry analysis and include plots of forward scatter (FSC)/side scatter (SSC) to exclude
cellular debris, anti-CD11c/anti-DCSIGN staining to identify the MDDC population, and DC-SIGN/p24Gag staining to identify productively infected MDDCs
in mock-infected or WT (Lai-YU2)- and ΔVpr-infected DCs. (B) Mean percentages ( standard errors of the means) of DC-SIGN intracellular
p24Gag-positive MDDCs determined from infections of cells derived from three donors as described above for panel A. (C) Replication kinetics of Lai-YU2
and Lai-YU2/ΔVpr in MDDCs infected at an MOI of 1. MDDC supernatants were harvested every 3 days and analyzed for p24Gag content by an ELISA. Data
shown are the means ( standard errors of the means) for three independent experiments with MDDCs derived from three independent donors. (D)
Schematic of the DC-T cell coculture setup. MDDCs were infected with Lai-YU2 or Lai-YU2/ΔVpr (MOI  1). At 2 days postinfection, autologous CD4
(Continued on next page)
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HIV-1/ΔVpr in MDDCs in the absence of any significant differences in gp120 expression
suggests that the previously hypothesized Vpr-dependent enhancement of gp120
production is unlikely to account for the observed replication defect in the present
study (28, 44).
Infection with Vpr-deficient HIV-1 does not induce type I IFN. Exposure of target
cells to type I IFN potently restricts HIV-1 replication in vitro (61–69). In addition, recent
studies suggested that infection with ΔVpr virus induces type I IFN (18, 28, 31–34).
Hence, we sought to determine if the induction of an early type I IFN response in
HIV-1/ΔVpr infections of MDDCs accounts for the restricted virus replication and spread.
MDDCs infected with the wild-type Lai-YU2 or Lai-YU2/ΔVpr virus were harvested at 48
h postinfection, and the mRNA expression levels of IFN- and the type I IFN-inducible
FIG 1 Legend (Continued)
T cells (PHA/IL-2 treated) were added at a 2:1 ratio to MDDCs or infected with cell-free virus in parallel (MOI  1). Supernatants were harvested on day
6 and day 9 postinfection (day 3 or 6 for cell-free CD4 T cell infection), and the p24Gag content in the culture supernatants was determined by an ELISA.
(E) Kinetics of p24Gag production in cell culture supernatants from a representative infection of MDDCs only, CD4 T cells only, or MDDC-CD4 T cell
cocultures. (F) Mean p24Gag contents ( standard errors of the means) present in the supernatants from infections of CD4 T cells only or MDDC-CD4
T cell cocultures at day 6 postinfection (day 3 postinfection for cell-free CD4 T cell infections). Data are representative of infections of five independent
donors. Significance was calculated by using paired Student’s t tests (*, P  0.05; **, P  0.01; ***, P  0.001).
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FIG 2 Vpr does not regulate Env expression in infected MDDCs or incorporation of Env into MDDC-derived virions. (A)
Western blot analysis of mock-infected, Lai-YU2 (WT)-infected, or Lai-YU2/ΔVpr-infected MDDCs (MOI  3) for p55Gag and
gp120 expression at day 6 postinfection. (B) Quantification of Western blots for p55Gag and gp120 in infected MDDCs, as
described above for panel A, from four independent experiments. The gp120 band intensity was quantified and
normalized to the p55Gag values from experiments with infected MDDCs derived from 4 donors. Data shown are means
( standard errors of the means). (C) Western blot analysis of p24Gag and gp120 expression in mock-infected, Lai-YU2
(WT)-infected, or Lai-YU2/ΔVpr-infected MDDCs (MOI  5). MDDC culture supernatants were harvested at days 3, 6, and
9 postinfection; pooled; and concentrated over a 20% sucrose cushion, and virus pellets were lysed for Western blot
analysis. (D) Quantification of data from Western blot analysis of MDDC-derived virions from three independent donors.
The band intensity for gp120 was quantified and normalized to the p24Gag band intensity. Data shown are means 
(standard errors of the means). Significance was calculated by using a one-sample t test (N.S., not significant [P  0.05]).
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protein interferon gamma-inducible protein 10 (IP-10) were quantified by RT-quan-
titative PCR (qRT-PCR). At 48 h post-virus exposure, we did not detect significant
increases in IFN- mRNA levels in wild-type- or ΔVpr-infected cells compared to
mock-infected cells (Fig. 3A). While the expression of the interferon stimulated gene
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FIG 3 Vpr deficiency does not result in enhanced type I IFN production in productively infected MDDCs. (A and B) qRT-PCR
for IFN- (A) and IP-10 (B) transcript levels in infected MDDCs at 48 h postinfection. MDDCs were mock infected or infected
with Lai-YU2 or Lai-YU2/ΔVpr (MOI  2) in the presence or absence of AZT (10 M). The amount of IFN- or IP-10 transcripts
in infected MDDCs was normalized to the number of cells by using a GAPDH control and is reported relative to that in
mock-infected MDDCs (set at a value of 1) from four independent donors. LPS treatment for 4 h was used as a positive control
for IFN- and IP-10 production. Data are the log-transformed means (standard errors of the means) of results for seven
donors. (C) The secreted level of IP-10 in MDDC culture supernatants infected with Lai-YU2 or Lai-YU2/ΔVpr (MOI  1) at day
3 postinfection was measured by an ELISA. The data shown are the log-transformed means ( standard errors of the means)
of results from independent experiments with MDDCs derived from four donors for panels A and B and from six donors for
panel C. Significance was calculated by using paired Student’s t test or a one-value t test (comparing normalized data) (NS,
not significant [P  0.05]; *, P  0.5; **, P  0.1; *****, P  0.0001).
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(ISG) IP-10 was robustly induced by the establishment of productive HIV-1 infection of
DCs, differences in IP-10 mRNA levels between WT and ΔVpr virus infections were not
statistically significant (Fig. 3B). Note that pretreatment of cells with zidovudine (AZT)
reduced the induction of IP-10 mRNA levels to those observed in mock-infected cells,
suggesting that the induction of IP-10 expression in virus-exposed cells was dependent
on de novo reverse transcription. In contrast, lipopolysaccharide (LPS) treatment of
MDDCs for 4 h resulted in robust increases of both IFN- and IP-10 mRNA levels (Fig.
3A and B). The inability to detect differences in the mRNA expression levels of IFN- in
MDDCs infected with the WT and ΔVpr viruses was also mirrored by the absence of
differences in protein levels in infected MDDC culture supernatants (data not shown).
We used a sensitive bioassay to measure type I IFN production in infected MDDC
supernatants and failed to detect any type I IFN production in HIV-1-infected MDDCs
over mock-infected controls (data not shown) (70). In contrast, IP-10 was robustly
secreted in both Lai-YU2 (WT)- and Lai-YU2/ΔVpr-infected MDDC culture supernatants
at day 3 postinfection, although the magnitude of IP-10 induction was donor depen-
dent (Fig. 3C). Furthermore, we observed a significant increase in IP-10 production
upon WT virus infection of MDDCs compared to mock-infected cells (Fig. 3C). Again,
AZT pretreatment reduced the secretion of IP-10, indicating that IP-10 production is
dependent on the completion of reverse transcription (Fig. 3C). Taken together, these
results suggest that Vpr deficiency does not result in the induction of type I IFNs during
the establishment of productive HIV-1 infection of MDDCs and is unlikely to play a role
in the restriction of HIV-1/ΔVpr in DCs.
Infection with Vpr viruses results in decreased infection in a single round of
replication and is rescued by virion-associated Vpr. To identify the step of the virus
replication cycle in MDDCs that is affected by Vpr, we next performed single-cycle-
infection analysis. MDDCs were infected with HIV-1 reporter viruses pseudotyped with
vesicular stomatitis virus G (VSV-G) and expressing luciferase upon the establishment of
infection that express (Lai-luc Δenv/G or the WT) or do not express (Lai-luc Δenv/G ΔVpr
or ΔVpr) Vpr. Infection with the ΔVpr virus resulted in a 3- to 5-fold decrease in
luciferase expression compared to that with infection with the WT virus (Fig. 4A),
C.A. B.
** ** **
Vpr
W
T
ΔV
pr
+H
A-
Vp
r
p55 
Gag
p24 
Gag
HA-Vpr
250
130
95
70
55
43
34
26
15
11
WT ΔVpr
0.0
0.5
1.0
1.5
N
or
m
al
iz
ed
 E
xp
re
ss
io
n
(R
LU
)
WT ΔVpr ΔVpr + HA-Vpr
0.0
0.5
1.0
1.5
N
or
m
al
iz
ed
 E
xp
re
ss
io
n
(R
LU
)
FIG 4 Infection of MDDCs with Vpr-deficient viruses results in a block to HIV-1 replication in single-round-infection analyses. (A) MDDCs infected
with 40 ng p24Gag equivalents of VSV-G-pseudotyped Lai-luc Δenv (WT or ΔVpr) were lysed at 3 days postinfection, and viral replication was
quantified by measuring luciferase activity in cell lysates. The luciferase activity in ΔVpr-infected cell lysates was normalized to that of WT
virus-infected MDDC lysates and is reported as the mean ( standard error of the mean) of data from four independent experiments with MDDCs
derived from four independent donors. (B) Western blot analysis of Vpr incorporation into virus particles (Lai-luc Δenv/G, Lai-luc Δenv/G ΔVpr,
or Lai-luc Δenv/G Vpr-trans) derived from transient transfection of HEK293T cells. (C) MDDCs were infected with 40 ng p24Gag equivalents of
viruses (Lai-luc Δenv, Lai-luc Δenv ΔVpr, or Lai-luc Δenv ΔVpr plus HA-Vpr) and lysed at 3 days postinfection. Cell lysates were analyzed for
luciferase activity, and the data shown are normalized to values for WT virus infection and are means (standard errors of the means) from 4
independent experiments. Significance was calculated by using paired Student’s t test or a one-value t test (comparing normalized data)
(**, P  0.01). RLU, relative light units.
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suggesting that Vpr acts early in the HIV-1 replication cycle in MDDCs at steps
preceding virion assembly and maturation. Since Vpr is a virion-associated protein, we
next sought to determine whether incoming virion-associated Vpr was sufficient or if de
novo-synthesized Vpr was required for the enhancement of virus replication in DCs. We
produced Lai-luc Δenv/G ΔVpr complemented with hemagglutinin (HA) epitope-tagged
Vpr in trans (Lai-luc Δenv/G Vpr-trans) via cotransfection of HEK293T cells with a
functional HA-Vpr expression plasmid and the Lai-luc Δenv/G ΔVpr proviral plasmid.
HA-Vpr was efficiently incorporated into ΔVpr virus particles to levels similar to those
observed for WT virus particles (Fig. 4B). We then infected MDDCs with Lai-luc Δenv/
G-WT, ΔVpr, or Vpr-trans viruses and lysed the cells on day 3 postinfection. The
incorporation of Vpr in trans within incoming virus particles rescued ΔVpr virus infec-
tion in a single-round assay (Fig. 4C), suggesting that virion-incorporated Vpr is
sufficient for overcoming cell-intrinsic blocks to early steps in HIV-1 replication in DCs.
Proviral LTR-mediated transcriptional activity is attenuated in Vpr-deficient
virus infection of DCs. Since the block to HIV-1/ΔVpr infection in MDDCs is evident
within a single round of replication and is independent of the mode of virus entry
(VSV-G-pseudotyped virus infection was also restricted) (Fig. 4A), we assessed the effect
of Vpr deficiency on HIV-1 RT and integration efficiency in DCs. We used quantitative
PCR (qPCR) to measure RT products and the number of proviruses at day 3 postinfec-
tion using the R-U5 and Alu-Gag primer pairs, respectively (71, 72). Infections were also
performed in the presence of AZT to control for contaminating input plasmid DNA. In
contrast to previously reported findings (41), we saw no decrease in the number of RT
products (Fig. 5A) or integrants (Fig. 5B and C) upon infection with the ΔVpr virus
compared to WT virus infections (Fig. 5A to C). Previous studies suggested that Vpr can
modulate HIV-1 long terminal repeat (LTR) transcriptional activity (29, 46, 73–75). We
therefore asked if the block to HIV-1/ΔVpr infection occurs at the stage of viral
transcript production. To determine the effect of Vpr on LTR-mediated transcription
from proviruses, we used qRT-PCR to measure multiply spliced tat-rev-nef transcripts at
48 h postinfection (Fig. 5D). Similar to our findings with luciferase reporter expression
in infected DCs, we observed a 4-fold decrease in the number of multiply spliced HIV-1
transcripts in HIV-1/ΔVpr-infected cells, suggesting that Vpr deficiency results in the
inhibition of proviral LTR-mediated transcription in DCs.
We next sought to determine if the decrease in multiply spliced viral mRNA levels
in HIV-1/ΔVpr-infected MDDCs was driven by changes in the pattern of viral mRNA
splicing. We used a novel Primer ID-tagged deep-sequencing assay (76, 77) to deter-
mine the relative abundances of different splice variants in WT- and ΔVpr-infected DCs
and compared the viral splice site usage to those observed in WT- or ΔVpr-infected
CD4 T cells and HeLa cells (Fig. 5E to G). The data depict the relative quantity of 4-kb
singly spliced mRNAs for each splice acceptor and are reflective of the changes
observed in the 1.8-kb multiply spliced mRNA (data not shown). We detected minor
differences in splice acceptor usage between WT and ΔVpr infections of MDDCs. We
observed small decreases in the use of the Vif (A1) and Vpr (A2) splice acceptors and
a small increase in the use of the Tat (A3) splice acceptor, but these differences were
well within the normal range of splicing variation seen in productive viral infections
(77). These small differences in splice site usage were consistently observed in infec-
tions of CD4 T cells and HeLa cells. Since the differences in splicing are both relatively
small and observed in two cell types (primary activated CD4 T cells and HeLa cells)
that do not restrict ΔVpr virus replication, it is unlikely that the efficiency of viral mRNA
splicing or the choice of mRNA splice acceptor sites is a factor that contributes to the
restricted replication of the ΔVpr virus in MDDCs.
Mutations in the C-terminal end of Vpr or those that disrupt binding to the
CRL4DCAF1 ubiquitin ligase attenuate viral replication in DCs. A range of functions
have been attributed to Vpr, including G2/M cell cycle arrest, enhancement of the
fidelity of reverse transcription, nuclear import and/or nuclear tethering of the prein-
tegration complex, and induction of apoptosis (12–14, 30, 41, 46, 78). To clarify which
of the known functions of Vpr are important for enhancing HIV-1 replication in DCs, a
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panel of mutations was introduced into a Vpr open reading frame (ORF) with previously
characterized effects on Vpr functions. HEK293T-derived virus particles were analyzed
by quantitative Western blotting to assess the incorporation of mutant Vpr proteins
into viral particles (Fig. 6A). While all viral mutants expressed and incorporated Vpr in
virus particles, the Vpr-F34I and Vpr-H71R mutants had slightly decreased levels of
incorporation of Vpr compared to those of wild-type viruses (Fig. 6A), although both
the wild-type and Vpr mutant viruses were equally infectious to TZM-bl cells on a
per-particle basis (Fig. 6B). MDDCs were infected with replication-competent HIV-1 (WT
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or Vpr mutants) at equal MOIs, and the extent of viral replication was measured by
periodic quantification of p24Gag levels in cell-free culture supernatants by an ELISA
(Fig. 6C). Since there was donor-to-donor variability in the kinetics and extent of virus
replication in DCs, we calculated the area under the curve of replication kinetics
obtained from four independent infections (Fig. 6D). As depicted in Fig. 6C and D,
infection with both the Vpr-Q65R and Vpr-H71R mutant viruses resulted in significantly
attenuated virus replication and spread, similar to what was observed for ΔVpr virus
replication in MDDCs (Fig. 6C and D). In contrast, the replication of both the Vpr-F34I
and Vpr-W54R mutants was not significantly different from that observed with wild-
type virus infections (Fig. 6C and D). Cumulative analysis revealed that the replication
of the Vpr-Q65R and Vpr-H71R mutants, which lack the ability to associate with the
CRL4DCAF1 complex (16–18, 30, 45, 46, 49, 79, 80), was significantly reduced (P  0.01),
similar to what was observed for ΔVpr virus infection (Fig. 6D). Interestingly, the
replication of the Vpr-F34I mutant, which incorporates reduced levels of Vpr in virions
(Fig. 6A) and displays a reduced association with the nuclear envelope (30, 45, 50), was
slightly enhanced over that observed for wild-type virus replication (P  0.01) (Fig. 6D),
suggesting that a threshold amount of functional Vpr that is still present in the
incoming virus particle is sufficient for the establishment of productive infections in
DCs. Mutation Vpr-W54R, which ablates the binding of Vpr to UNG2 (19, 45, 80–82), had
a negligible effect on viral replication in DCs.
We next sought to determine which of these Vpr mutants could recapitulate the
single-cycle replication defect observed for HIV-1/ΔVpr infection of MDDCs (Fig. 4A). We
infected MDDCs with either replication-competent viruses (Lai-YU2 WT or Vpr mutants)
(MOI 1) in the presence of a protease inhibitor (indinavir) or equal amounts of p24Gag
equivalents of Lai-luc Δenv/G encoding the various Vpr mutations. Similar to the results
observed with replication-competent viruses, both the number of p24Gag-postitive cells
(Fig. 6E) and the level of luciferase production (Fig. 6F) from infections with the
Vpr-Q65R and Vpr-H71R mutants were significantly attenuated in a single round of
infection compared to isogenic WT viruses. While the host protein targeted by HIV-1
Vpr to induce G2 cell cycle arrest has not been identified, the C-terminal tail of this
protein has been proposed to bind the unknown host factor, and mutations in the
C-terminal tail of Vpr abrogate the ability of Vpr to induce G2 cell cycle arrest (45). To
determine the role of Vpr-mediated G2 cell cycle arrest in virus infection enhancement
in DCs, an additional mutation, Vpr-R90K, was introduced into a green fluorescent
protein (GFP)-expressing single-cycle virus (Lai-GFP Δenv/G). The Vpr-R90K mutant can
bind the CRL4DCAF1 complex but fails to induce G2 arrest in cycling cells (45, 50, 80).
Despite equivalent incorporation into the virion as WT Vpr (Fig. 6G), infection of MDDCs
with the Vpr-R90K mutant resulted in a significant infection defect in single-round
analyses (Fig. 6H), similar to what was observed in infections with ΔVpr or Vpr-Q65R
viruses, suggesting that an interaction with a putative host factor whose degradation
FIG 6 Legend (Continued)
units (blue cells) per nanogram of p24Gag equivalent, and results are the means ( standard errors of the means) of data from
three independent viral preparations. (C) Viral growth curves for four independent infections of MDDCs with Lai-YU2 and the
indicated Vpr mutants in DCs. Viral growth was determined by analyzing p24Gag release into cell culture supernatants at days
3, 6, 9, and 12 postinfection by an ELISA. (D) Areas under the curve compiled for four independent MDDC infections
represented in panel C, normalized to the value for WT virus infection, which was set to 1 (means  standard errors of the
means). (E) Percentage of p24Gag-positive MDDCs at day 3 postinfection as measured by intracellular p24Gag staining and FACS
analysis. Cells were treated with indinavir (1 M) post-virus exposure to prevent viral spread. The data were normalized to the
value for WT virus infection, which was set to 1, and depict the means ( standard errors of the means) of results from three
independent infections of MDDCs from three donors. (F) MDDCs infected with 40 ng p24Gag equivalents of Lai-luc Δenv/G (WT
or Vpr mutants) were lysed at 3 days postinfection, and viral replication was quantified by measuring luciferase activity in cell
lysates. The luciferase activity in Vpr mutant infections was normalized to that of WT virus infections, which was set to 1, and
the data shown are the means ( standard errors of the means) for three independent experiments. (G) Western blot analysis
of HEK293T-derived Lai-GFP Δenv/G (WT) virus particles or the indicated Vpr mutant virus particles. (H) MDDCs infected with
Lai-GFP Δenv/G (WT) or the indicated Vpr mutants (MOI  3) were harvested at day 3 postinfection and processed for FACS
analysis. The data shown are the mean percentages of GFP-positive cells ( standard errors of the means) from five
independent experiments with cells derived from five independent donors. Significance was calculated by using paired
Student’s t test or a one-value t test (comparing normalized data) (*, P  0.05; **, P  0.01; ***, P  0.001; ****, P  0.0001).
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is critical for the induction of G2 cell cycle arrest is required to enhance HIV-1 infection
of DCs. Together, our data suggest that there is a novel block to HIV-1 infection in
MDDCs in the absence of Vpr that is present in a single round of infection and manifests
at the stage of viral transcription. Further studies are under way to determine the exact
mechanism by which Vpr alleviates the DC-intrinsic block to HIV-1 replication.
DISCUSSION
In the work presented here, we examined the role of Vpr in establishing productive
HIV-1 infection of DCs. Previous work in this field suggests that Vpr likely regulates a
complex network of host interactions that may vary depending on the cell type
infected. We find that, unlike what has been previously observed in activated CD4 T
cells and monocyte-derived macrophages (20, 22–25, 29), infection of MDDCs with
ΔVpr viruses was significantly attenuated compared to WT HIV-1 infections (Fig. 1),
similar to the findings reported previously by de Silva et al. (41). Interestingly, Vpr-
mediated enhancement was observed for both single-round viral infection as well as
spreading infections, contrary to what was reported previously (28, 41). Furthermore,
the single-round replication defect could be rescued by complementing back Vpr in
trans in the incoming virion (Fig. 4), indicating that incoming virion-associated Vpr is
necessary for the establishment of efficient HIV-1 infection of DCs. Initiating infections
with the Vpr mutants Vpr-Q65R, Vpr-H71R, and Vpr-R90K, which lack the ability to either
engage the CRL4DACF1 complex or bind the yet-to-be-identified host factor(s) necessary
for inducing G2 cell cycle arrest, displayed replication deficits similar to those observed
for the ΔVpr virus in both spreading infections and single-round infections (Fig. 6).
Surprisingly, the block to ΔVpr virus replication in MDDCs was evident at a postin-
tegration step and resulted in reduced numbers of viral mRNAs, suggesting that Vpr is
acting either directly or indirectly to enhance transcription from the viral LTR (Fig. 5). It
was reported previously that Vpr can transactivate the viral LTR in a number of cell
types and that this function correlates with the ability of Vpr to induce G2 cell cycle
arrest (26, 29, 46, 73, 75). Previous studies have also shown that Vpr of both simian
immunodeficiency viruses (SIVs) SIVmac and SIVagm can also transactivate their respec-
tive LTRs (74, 83, 84), suggesting that this is a conserved function among nonhuman
primate lentiviral Vpr proteins. While it is possible that Vpr-mediated transactivation
could be more robust in DCs than in CD4 T cells (Fig. 1E), another hypothesis is that
Vpr indirectly activates transcription to promote infection in cells that have a higher
barrier to infection.
Unlike most of the other lentiviral accessory proteins, Vpr is actively packaged into
the budding virion through associations with the p6 region of Gag (3–6, 10). Our work
with MDDCs suggests that there may be a novel role for virion-associated Vpr to
enhance viral transcription and increase infection of DCs. These findings are at odds
with data from recently reported studies on the role of Vpr in modulating de novo HIV-1
Env production in productively infected macrophages and MDDCs (28, 44). While we
occasionally see a decrease in viral Env production during infection with the ΔVpr virus
in MDDCs (one out of four donors tested), infection of MDDCs from most of the donors
revealed no differences in Env expression or virion incorporation (Fig. 2). It is possible
that the use of different viral clones, primary cell variation derived from multiple
donors, or different infection conditions might play a role in the differences between
our results and those described previously. Since we observed infection differences in
a single-round-infection assay, putative effects of Vpr on Env expression are unlikely to
play a role in the establishment and spread of virus infection in MDDCs and DC-T cell
cocultures.
HIV-1 is not unique among primate lentiviruses in expressing a protein that func-
tionally allows infection of DCs. HIV-2 and certain SIV lineages express Vpx, another
small accessory protein that targets the host restriction factor SAMHD1 for proteosomal
degradation by recruiting it to the CRL4DACF1 complex and facilitates infection of
MDDCs (51, 52, 85). Interestingly, Vpr-mediated replication enhancement in MDDCs
was substantially attenuated upon infection with Vpr mutants (Q65R or H71R) (Fig. 6F)
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that lack the ability to interact with the CRL4DCAF1 complex or upon infection with the
Vpr-R90K mutant (Fig. 6H) that fails to interact with the host factor(s) hypothesized to
be recruited to the CRL4DCAF1 complex for proteosomal degradation. Since Vpr is
introduced into target cells along with the incoming virion because of its association
with the viral capsid, we hypothesize that early interactions of Vpr with a host factor
and the recruitment of this protein to the CRL4DCAF1 complex for proteosomal degra-
dation are essential for promoting HIV-1 replication in DCs, similar to the ability of Vpx
from SIVmac/SIVsmm/HIV-2 lineages to promote infection of DCs.
Across primate lentiviral Vpr evolution, the induction of the DDR and G2 cell cycle
arrest are conserved functions, and Vpr proteins from diverse primate lentiviruses have
been shown to associate with and degrade many DDR regulatory proteins, including
SLX4com, HLTF, and UNG2 (18–21, 80, 81, 86–89). While DDR activation may represent
a cell-intrinsic antiviral response, it has been suggested that both RNA and DNA viruses
induce DDR signaling to promote cellular conditions that are favorable for viral
replication (83, 90–93). For instance, the induction of DDR signaling activates ataxia
telangiectasia mutated (ATM) kinase, which results in the activation of nuclear factor
kappa light chain enhancer of activated B cells (NF-B) (94, 95). Additionally, the DDR
pathway also directly activates proinflammatory responses through the induction of
interferon regulatory factors (IRFs) or through the recruitment of coactivators and
chromatin-modifying complexes, such as ten-eleven translocation methylcytosine (TET)
dioxygenases, which we hypothesize might also activate viral transcription (96). Since
the barrier to the successful establishment of infection in noncycling, metabolically
quiescent cells like MDDCs is higher than that in activated CD4 T cells or MDMs, the
Vpr-mediated activation of NF-B and coactivator recruitment to the viral LTR might be
a viral strategy for overcoming the restrictive cellular environment and for the optimal
production of progeny virions. In line with this hypothesis, numerous studies have
documented that Vpr is able to modulate NF-B activity in different cell lines and
primary cells, although those studies rarely agree on the mechanism of regulation or
direction of modulation (26, 75, 97–102). Recent work by Höhne et al. shows similar
effects of Vpr on viral replication in nonactivated primary CD4 T cells (26), which have
barriers to infection similar to those of MDDCs, including increased expression of
SAMHD1 and low baseline NF-B activity (103, 104). Some studies have shown that
virion-associated Vpr-dependent activation of NF-B occurs via a transforming growth
factor -activated kinase 1 (TAK1) signaling cascade, while other studies have shown
that secreted or synthetic Vpr stimulates NF-B signaling through a Toll-like receptor 4
(TLR4)-dependent mechanism (75, 99, 100, 102). Our data also demonstrate the up-
regulation of IP-10 upon HIV-1 (WT) infection (Fig. 3C), which is also dependent on
NF-B activation (105–107).These results suggest a link between Vpr-mediated NF-B
activation in MDDCs and enhanced viral gene expression and proinflammatory cyto-
kine secretion, which may act in vivo to enhance recruitment, activation, and infection
of CD4 T cells, resulting in increased viral dissemination (Fig. 1E) (27, 75, 99).
Previous studies with peripheral blood myeloid MDDCs and MDDCs from HIV-1 elite
controllers have shown that these cells may be critical for viral control, acting to capture
the virus and enhance T cell-specific immunity to HIV-1 while being less susceptible to
HIV-1 infection than MDDCs from healthy controls (108, 109). Understanding the
mechanisms that control HIV-1 replication in MDDCs, which are overcome by Vpr,
might lead to new insights into viral dissemination and persistence in vivo and the
development of novel anti-HIV-1 therapeutics.
MATERIALS AND METHODS
Plasmids. HIV-1 proviral plasmids Lai-YU2 env, Lai/Bal, Lai-luc Δenv (Env-deficient HIV-1 containing
a luciferase reporter gene in place of nef), and Lai-GFP Δenv (Env-deficient HIV-1 containing GFP in place
of nef) and the HA-Vpr expression plasmid were previously described (30, 110). Proviral Lai (CXCR4-tropic)
clones containing Vpr mutations F34I, W54R, and H71R and a frameshift mutation in Vpr (ΔVpr) were
described previously (30, 46, 80, 111). These Vpr mutations were transferred to the Lai-YU2 env, Lai-luc
Δenv, or Lai-GFP Δenv proviral plasmids using ApaI and SalI restriction sites. To create proviral clones
encoding the Vpr-Q65R mutation, the ApaI-SalI fragment of Lai-YU2 env was subcloned into the pSL1180
cloning vector (Stratagene), and site-directed mutagenesis was performed by using a kit (QuikChange II;
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Agilent Technologies) and the following primers: 5=-GCCATAATAAGAATTCTGCGACAACTGCTGTTTATCC
ATTTC-3= and 5=-GAAATGGATAAACAGCAGTTGTCGCAGAATTCTTATTATGGC-3=. The mutated fragment
was ligated back into Lai-YU2 env, Lai-luc Δenv, or Lai-GFP Δenv using ApaI-SalI restriction sites. The
point mutation Vpr-R90K was derived by subcloning the SalI-BamHI fragment into pSL1180 and via
site-directed mutagenesis (QuikChange II; Agilent Technologies) using the following primers: 5=-CGTTA
CTCAACAGAGGAGAGCAAAAAATGGAGCCAGTAGATCCTAGAC-3= and 5=-GTCTAGGATCTACTGGCTCCATTT
TTTGCTCTCCTCTGTTGAGTAACG-3=. The mutated fragment was cloned back into Lai-GFP Δenv.
Cells and viruses. MDDCs were derived from monocytes isolated from peripheral blood mononu-
clear cells as previously described (112). TZM-bl and HEK293T cells were described previously (112–114).
Replication-competent Lai-YU2 env viruses were derived by using calcium phosphate-mediated transient
transfection of HEK293T cells, as described previously (115). HIV-1 vectors were generated from HEK293T
cells via the cotransfection of Lai-luc Δenv or Lai-GFP Δenv with a VSV-G expression plasmid. Virus-
containing cell supernatants were harvested at 2 days posttransfection, passed through 0.45-m filters,
and stored at 80°C until further use. For some experiments, virus particles were concentrated by
ultracentrifugation on a 20% sucrose cushion (24,000 rpm at 4°C for 2 h with an SW28 rotor [Beckman
Coulter]) (116). The virus pellets were resuspended in phosphate-buffered saline (PBS), aliquoted, and
stored at 80°C until use. The capsid content of HIV-1 was determined by a p24Gag ELISA, while the
infectious titer was determined via infection of TZM-bl cells (114, 117). Viral replication in MDDCs and
DC-T cell cocultures was determined by measuring the p24Gag content in cell culture supernatants at the
indicated days postinfection by an ELISA (117). Infection of MDDCs using a luciferase reporter virus was
analyzed by using the Bright-Glo luciferase system (Promega), as previously described (118).
Drug treatments. For the indicated experiments, cells were pretreated with AZT (10 M; NIH AIDS
Research and Reference Reagent Program) for 30 min at 37°C prior to infection, and the AZT concen-
tration was maintained for the duration of the cultures, or cells were treated with indinavir (1 M; NIH
AIDS Research and Reference Reagent Program) post-virus exposure.
Quantitative Western blotting. To detect Gag and Env in cell and virus particle lysates, cell lysates
(normalized to equivalent amounts of cell-associated Gag) or 100 ng p24Gag virus equivalents (as
determined by a quantitative ELISA) was run through SDS-PAGE gels and transferred onto nitrocellulose
membranes by using a semidry transfer apparatus, as previously described (116). Blots were blocked and
probed with rabbit anti-gp120 (a gift from Nancy Haigwood) and mouse anti-p24Gag (clone p24-2; NIH
AIDS Research and Reference Reagent Program), followed by goat anti-mouse IgG DyLight 680 (Pierce)
and goat anti-rabbit IgG DyLight 800 (Pierce). To determine Vpr incorporation, a polyclonal rabbit
anti-Vpr antibody (clone 1-50; NIH AIDS Research and Reference Reagent Program) was used, followed
by goat anti-rabbit IgG DyLight 700. The membranes were scanned with an Odyssey scanner (Li-Cor).
qRT-PCR. For the quantitation of IFN- and IP-10 mRNA levels, MDDCs (2	 106 to 4	 106 cells) were
mock infected or infected with Lai-YU2 or Lai-YU2/ΔVpr (MOI  2). At 48 h postinfection, cells were
harvested for RNA isolation by using RNeasy RNA isolation kits (Qiagen), and cDNA was synthesized by
using oligo(dT) primers and Superscript III RT (Invitrogen). cDNA corresponding to 200 ng of RNA was
analyzed by qRT-PCR using SYBR green (Invitrogen) to quantify mRNA levels for IFN- (forward primer
5=-ATTCTAACTGCAACCTTTCG-3= and reverse primer 5=-GTTGTAGCTCATGGAAAGAG-3=), IP-10 (forward
primer 5=-TCATTGGTCACCTTTTAGTG-3= and reverse primer 5=-AAAGCAGTTAGCAAGGAAAG-3=), and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (forward primer 5=-AGGGATGATGTTCTGGA
GAG-3= and reverse primer 5=-CAAGATCATCAGCAATGCCT-3=). The ΔΔCT value relative to GAPDH in the
mock-infected cultures was set to 1, and data from the infected cultures are reported as fold enhance-
ments. To determine the extent of de novo viral transcription, the number of tat-rev-nef multiply spliced
transcripts was determined by qRT-PCR using SYBR green, as described previously (58), with the
following primer set: forward primer 5=-GCGACGAAGACCTCCTCAG-3= and reverse primer 5=-GAGGTGG
GTTGCTTTGATAGAGA-3=. The data were normalized to GAPDH levels. As a control, MDDCs were treated
with AZT (10 M) for 30 min prior to infection, and drug levels were maintained during the course of
infection.
Quantification of viral integration. To determine the number of proviral integrants, MDDCs (3 	
106 cells) were infected with the virus (MOI  3) for 2 h at 37°C, washed with PBS twice, and cultured
for 72 h before cells were lysed for DNA extraction with a DNeasy kit (Qiagen). As a background control,
MDDCs were treated with 10 M AZT for at least 30 min prior to infection. Quantitative Alu PCR was
performed by using 20 ng of DNA with the following primer sets, as described previously (72). For the
first step, the following primers were used: Alu-forward (5=-GCCTCCCAAACTGCTGGGATTACAG-3=) and
Gag-reverse (5=-GCTCTCGCACCCATCTCTCTCC-3=). For the second step, the following primers and probe
were used: primers R-U5-F (5=-GCCTCAATAAAGCTTGCCTTGA-3=) and R-U5-R (5=-TCCACACTGACTAAAAG
GGTCTGA-3=) and probe R-U5-Probe (5=–6-carboxyfluorescein [FAM]–CCAGAGTCACACAACAGACG–6-ca
rboxytetramethylrhodamine [TAMRA]–3=). The data were normalized to a standard curve generated from
infected HEK293 cell DNA (71, 72).
Splicing assay. The splicing assay was described in detail previously (77). Briefly, cDNA primers with
an internal random sequence block, as denoted by Ns in their sequences (Primer ID) (76), were designed
to be located within the env intron to measure the 4-kb size class of spliced viral RNAs or to span the
D4/A7 splice junction to measure the 1.8-kb size class. The reverse primer for the 4-kb size class was
5=-GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTNNNNNNNNNNNNNNGTACGCTAATACTTGTAAAGATT
GCAGTACATGTACTACTT-3=, and the reverse primer for the 1.8-kb size class was 5=-GTGACTGGA
GTTCAGACGTGTGCTCTTCCGATCTNNNNNNNNNNNNNNCAGTCTGAGCTGGGAGGTGGGTTGC-3=. Whole-cell
RNA from infected cells was purified and used in a cDNA reaction. After the removal of the cDNA primers, PCR
was carried out by using a downstream primer encoded in the cDNA primer tail and a forward primer placed
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just upstream of the D1 major donor site in the 5= noncoding region, 5=-GCCTCCCTCGCGCCATCAGAGATGT
GTATAAGAGACAGNNNNTGCTGAAGCGCGCACGGCAAG-3=. PCR products were sequenced by using the
MiSeq platform, and sequence reads with the same Primer ID were collapsed into a single read (to
correct for skewing during PCR, since each unique Primer ID tag represents a separate viral mRNA
template). Data were processed by using customized scripts that are available upon request. The
number of unique Primer IDs for each spliced product was used to determine the relative level of
splicing from each splice donor to each splice acceptor in the viral genome, with the exception of
splicing events for the nef splice acceptor A7.
Cytokine measurements. The secreted level of IP-10 in MDDC culture supernatants was measured
by using a commercially available ELISA kit (Becton Dickinson). Secreted levels of bioactive type I IFN in
infected MDDC supernatants were measured by using a HEK293 ISRE-luc cell line, which expresses
luciferase under the control of an IFN-inducible promoter carrying the IFN-stimulated response element
(70). Briefly, HEK293 ISRE-luc cells (8 	 104) were incubated with MDDC culture supernatants for 21 h.
Cells were lysed, and luciferase activity in the cell lysates was analyzed with the Bright-Glo luciferase
system (Promega), as described above. Serial dilutions of recombinant interferon alpha ranging from 200
to 0.39 U/ml (PBL Interferon Source) were added to cells in each experiment for generating a standard
curve.
FACS analysis. Intracellular fluorescence-activated cell sorter (FACS) analysis for p24Gag was done by
using fluorescein isothiocyanate (FITC)-conjugated anti-p24Gag monoclonal antibody (KC57; Coulter), as
previously described (117). Surface staining for CD11c was done by using allophycocyanin (APC)-
conjugated anti-CD11c (clone B-ly6; Becton Dickinson). Cells were analyzed by using either an LSRII or a
FACSCalibur (Becton Dickinson) instrument.
Ethics statement. This work has been deemed exempt by the Institutional Review Board of Boston
University School of Medicine, since it does not meet the definition of human subjects research. All
human samples used were collected in an anonymous fashion and no identifiable private information
was collected.
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